Market open · Oct 8, 11:40 am ET · After hours $4.30 +0.23%
Open$4.22
Prev close$4.29
Day range$4.05 – $4.30
Volume1.62M
Market cap$807.76M
P/E (TTM)5.2
Dividend yield–
ABUS Stock News
Headlines matching Arbutus Biopharma or the ABUS ticker, most recent first.
Earnings Flash (ABUS) Arbutus Biopharma Posts Q1 EPS $0.87, Vs. FactSet Est of $0.03 LossNegativeMT Newswires · 13 May 2026 · Direct mention
Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Total Revenue $14.1M, Vs. FactSet Est of $13.6MMT Newswires · 23 Mar 2026 · Direct mention
Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Loss $0.17 a Share, Vs. FactSet Est of $0.19 LossNegativeMT Newswires · 23 Mar 2026 · Direct mention
ABUS Stock Has Given up Its Prior Gain. Arbutus Biopharma Shares Were Trading Higher After the Company Presented Clinical Trial Data From Its Two HBV Assets.PositiveBenzinga · 7 May 2025 · Direct mention
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5Market news · 31 Mar 2025 · Direct mention
Earnings Flash (ABUS) Arbutus Biopharma Corporation Reports Q3 Revenue $529,000, Vs. FactSet Est of $1.3MMT Newswires · 13 Nov 2025 · Direct mention
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5Market news · 21 Jan 2025 · Direct mention
Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7PositiveMarket news · 6 Sep 2024 · Direct mention
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4Market news · 2 Aug 2024 · Direct mention
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5PositiveMarket news · 2 Aug 2024 · Direct mention
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5PositiveMarket news · 7 Nov 2024 · Direct mention
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5PositiveMarket news · 20 Nov 2024 · Direct mention
H.C. Wainwright Keeps Their Buy Rating on Arbutus Biopharma (ABUS)TipRanks · 12 Sep 2023 · Direct mention
Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)TipRanks · 8 Aug 2023 · Direct mention
H.C. Wainwright Sticks to Their Buy Rating for Arbutus Biopharma (ABUS)TipRanks · 4 Aug 2023 · Direct mention
Discussion
No comments yet — be the first to weigh in on ABUS.
No comments yet — be the first to weigh in on ABUS.